The Manufacturers Life Insurance Company Acquires Shares of 17,159 TransMedics Group, Inc. $TMDX

Key Points

• The Manufacturers Life Insurance Company acquired 17,159 TransMedics Group shares worth approximately $1.14 million, while institutional investors collectively own 99.67% of the stock.
• Analyst sentiment is mixed: six analysts rate TMDX a Buy, six rate it Hold, and one rates it Sell. The consensus rating is Hold, with an average price target of $124.18.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above estimates, but earnings of $0.44 per share missed the $0.50 consensus forecast.

The Manufacturers Life Insurance Company acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 17,159 shares of the company's stock, valued at approximately $1,140,000.

A number of other large investors have also recently made changes to their positions in TMDX. Harvest Fund Management Co. Ltd bought a new position in shares of TransMedics Group in the 3rd quarter valued at about $29,000. Allworth Financial LP increased its stake in TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company's stock worth $30,000 after acquiring an additional 113 shares during the last quarter. Parallel Advisors LLC increased its stake in TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company's stock worth $34,000 after acquiring an additional 83 shares during the last quarter. Ascentis Independent Advisors purchased a new stake in TransMedics Group during the first quarter valued at approximately $30,000. Finally, North Star Investment Management Corp. purchased a new stake in TransMedics Group during the first quarter valued at approximately $30,000. 99.67% of the stock is currently owned by institutional investors.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director directly owned 16,642 shares in the company, valued at $1,249,148.52. This represents a 36.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on TMDX shares. Stifel Nicolaus lifted their target price on TransMedics Group from $75.00 to $80.00 and gave the stock a "hold" rating in a report on Thursday, June 18th. Wall Street Zen downgraded TransMedics Group from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. UBS Group dropped their price objective on shares of TransMedics Group from $80.00 to $77.00 and set a "neutral" rating for the company in a research note on Wednesday, August 5th. Piper Sandler reissued an "overweight" rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Finally, Needham & Company LLC lowered their target price on shares of TransMedics Group from $142.00 to $106.00 and set a "buy" rating for the company in a report on Monday, August 3rd. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $124.18.

TransMedics Group Trading Up 3.4%

Shares of NASDAQ TMDX opened at $89.98 on Friday. TransMedics Group, Inc. has a twelve month low of $60.10 and a twelve month high of $156.00. The firm has a market cap of $3.11 billion, a PE ratio of 23.13 and a beta of 1.90. The business has a fifty day simple moving average of $80.14 and a two-hundred day simple moving average of $92.21. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.06). The firm had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.TransMedics Group's quarterly revenue was up 20.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.92 EPS. Analysts expect that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.